Sigachi Industries Limited (NSE:SIGACHI)
27.84
+0.26 (0.94%)
Nov 12, 2026, 3:30 PM IST
Sigachi Industries Revenue
Sigachi Industries had revenue of 1.30B INR in the quarter ending September 30, 2026, with 15.47% growth. This brings the company's total for the last twelve months to 4.91B, down -3.49% year-over-year. In the fiscal year ending March 31, 2026, Sigachi Industries had annual revenue of 4.78B, down -4.50%. That makes Sigachi Industries the 27,645th largest company in the world by revenue and 1,840th in India.
Revenue (ttm)
4.91B
Revenue Growth
-3.49%
P/S Ratio
2.17
Revenue / Employee
3.51M
Employees
1,400
Market Cap
10.64B
Revenue by Geography
- Export 2.65B 55.4%
- India 1.59B 33.3%
- Unallocated 539.38M 11.3%
Fiscal year ended Mar 31, 2026 See the full Sigachi Industries breakdown
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Mar 31, 2026 | 4.78B | -224.98M | -4.50% |
| Mar 31, 2025 | 5.00B | 962.25M | 23.81% |
| Mar 31, 2024 | 4.04B | 1.02B | 33.79% |
| Mar 31, 2023 | 3.02B | 517.55M | 20.68% |
| Mar 31, 2022 | 2.50B | 544.85M | 27.83% |
| Mar 31, 2021 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Mar 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. It does not take any expenses into account and is therefore different from profits.
Related Stocks
| Company Name | Revenue |
|---|---|
| Indoco Remedies | 19.09B |
| Solara Active Pharma Sciences | 15.35B |
| Windlas Biotech | 9.93B |
| Ind-Swift Laboratories | 7.64B |
| Beta Drugs | 4.10B |
| Valiant Laboratories | 3.77B |
| Jagsonpal Pharmaceuticals | 3.16B |
| Amanta Healthcare | 3.04B |